Althea offers cGMP plasmid production, protein production, formulation and filling services. Plasmid DNA and protein production are offered using both Althea’s industry-leading manufacturing process as well as client developed processes. A range of options are available for formulation and filling services ranging from semi- automated to fully- automated processes for vials and syringes. Althea is focused on offering highly responsive customer service, flexible scheduling, and rapid turnaround times to meet the requirements of both early stage clinical programs and commercial programs alike.
Althea Receives Manufacturing Contract From National Institutes of Health
SAN DIEGO – April 15, 2003 – Althea Technologies, Inc., a leading provider of gene-based manufacturing and testing services to accelerate drug development, announced today that it has received a four-year contract from the National Institutes of Health (NIH), U.S. Department of Health and Human Services, to assist the National Institute of Allergy and Infectious Diseases (NIAID) with the development, scale-up and production of candidate vaccines, as well as to perform the necessary characterization tests required for release of vaccines for clinical use.
“We appreciate the confidence the NIH has shown in Althea and our capabilities to manufacture vaccines, and are honored to be part of this important effort,” stated Dr. Magda Marquet, Co-President and Co-Chief Executive Officer, and Principal Investigator on the contract. “We believe our broad experience in both manufacturing and characterization testing will provide an excellent resource to organizations contracting for those services with the NIAID. We look forward to assisting the NIAID with its mission to discover ways to treat and prevent disease through collaborations with research institutes and private organizations.”
With over 1,000 vaccines in research and development worldwide for infectious diseases, cancer and other diseases, vaccines have become the fastest growing segment of the pharmaceutical industry.
“The timing of this award is terrific as we move into our new 30,000 square foot facility,” stated Rick Hancock, Senior Vice President of Operations. “We will have significantly greater capability to manufacture a variety of DNA and protein vaccines in a cGMP environment. We have also added the capability to formulate and fill clinical products in either syringes or vials. We look forward to supporting the NIAID’s vaccine production program.”
About Althea Technologies, Inc.
Althea’s focus is on accelerating gene-based drug development by supporting researchers worldwide in their attempts to understand the mechanisms of disease and to develop new therapeutics. Althea’s services include gene expression analyses using its proprietary eXpress Profiling™ technology, custom genomic analyses using real-time PCR, and cGMP plasmid DNA and protein production, and formulation and fill services. For more information, visit www.altheatech.com.Contact:
| Althea Technologies, Inc. Alan Moore Executive Vice President & Chief Business Officer (858) 882-0205 amoore@altheatech.com |
Althea Technologies
A leading provider of contract services to
the pharmaceutical and biotechnology industries
11040 Roselle Street | San Diego, CA 92121-1205
Toll-free 1-888-4ALTHEA
info@altheatech.com